Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.65 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | EPOR | P19235 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24712871 | 1.00 | GLP1R (0.65) | GLP1RFOLH1NOD1GLO1EPOR | |
| SCHEMBL23489667 | 1.00 | GLP1R (0.65) | GLP1RFOLH1NOD1GLO1EPOR | |
| SCHEMBL18202847 | 1.00 | GLP1R (0.65) | GLP1RFOLH1NOD1GLO1EPOR | |
| SCHEMBL23475917 | 1.00 | GLP1R (0.65) | GLP1RFOLH1NOD1GLO1EPOR | |
| SCHEMBL23475915 | 1.00 | GLP1R (0.65) | GLP1RFOLH1NOD1GLO1EPOR | |
| SCHEMBL23475960 | 1.00 | GLP1R (0.65) | GLP1RFOLH1NOD1GLO1EPOR | |
| SCHEMBL24711913 | 1.00 | GLP1R (0.65) | GLP1RFOLH1NOD1GLO1EPOR | |
| SCHEMBL23567477 | 0.94 | GLP1R (0.61) | GLP1RFOLH1NOD1 | |
| SCHEMBL24592948 | 0.94 | GLP1R (0.61) | GLP1RFOLH1NOD1 | |
| SCHEMBL23567479 | 0.94 | GLP1R (0.61) | GLP1RFOLH1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885FOLH1 10/4885NOD1 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.